Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)

Market Cap	12.05B +20.9%
Revenue (ttm)	10.55B +2.0%
Net Income	540.71M -10.1%
EPS	0.46 -11.5%
Shares Out	1.16B
PE Ratio	22.52
Forward PE	23.02
Dividend	0.21 (1.97%)
Ex-Dividend Date	n/a

Volume	32,256,525
Average Volume	12,370,654
Open	10.58
Previous Close	10.64
Day's Range	10.28 - 10.74
52-Week Range	8.13 - 13.06
Beta	0.38
RSI	56.68
Earnings Date	Apr 8, 2026

About SHA:600267

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss, anti-viral, anti-TB, animal healthcare, and others. The company also exports its products to approximately 70 countries worldwide. The company was fo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1956
• Employees: 7,994
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600267

Financial Performance

In 2025, SHA:600267's revenue was 10.55 billion, an increase of 7.79% compared to the previous year's 9.79 billion. Earnings were 540.71 million, a decrease of -10.06%.